CERIBELL, INC. – Trademark Portfolio

Entity Type: 03

CERIBELL, INC. holds 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered and 1 is pending. Notable registered marks include CLARITY, CERIBELL, and BRAIN STETHOSCOPE. The owner is based in Mountain View, CA.

2483 Old Middlefield Way, Suite 120

Mountain View, CA 94043

7 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

CERIBELL, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

10
Medical Apparatus (7 filings)

Surgical, medical, dental and veterinary apparatus and instruments

42
Computer & Scientific (3 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does CERIBELL, INC. have?

CERIBELL, INC. has 7 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 pending, 3 abandoned.

What trademark classes does CERIBELL, INC. file in?

CERIBELL, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.

What are CERIBELL, INC.'s most well-known trademarks?

CERIBELL, INC.'s registered trademark portfolio includes well-known marks such as CLARITY, CERIBELL, and BRAIN STETHOSCOPE. These are among 3 currently registered trademarks in the portfolio.

What is CERIBELL, INC.'s trademark registration success rate?

CERIBELL, INC. has a 50% trademark registration rate, with 3 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.